MedTrace Logo

Safety Study of HPP593 in Subjects During and After Limb Immobilization

NCT01524406 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-07-15

No results posted yet for this study

Summary

This is a safety and tolerability study investigating the effect of HPP593 in healthy volunteers during and after limb immobilization.

Conditions

  • Muscle Atrophy
  • Hypodynamia

Interventions

DRUG

HPP593

Oral, twice a day.

DRUG

Placebo

Oral, twice a day.

Sponsors & Collaborators

  • High Point Pharmaceuticals, LLC.

    lead INDUSTRY

Principal Investigators

  • Shulin Wang, M.D. · High Point Pharmaceuticals, LLC.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01524406 on ClinicalTrials.gov